AMGNAmgen Inc.
$447.28+2.04%
0.1% Above PivotData as of Oct 22, 2026
Loading theme radar
Obesity and GLP-1 Stocks
Commercial GLP-1 leaders, next-generation metabolic drug developers, diabetes devices, and digital health platforms.
3M Return+5.3%
YTD Return-0.6%Year to date
vs SPY (3M)+0.8%Theme minus SPY
Total Stocks22Curated universe
Setup Distribution
Breaking Out7
Near Pivot0
Forming1
Total Setups8
Theme vs SPY (3M)
GLP-1 Stocks+3.8%
SPY+2.9%
Top Setups in GLP-1 Stocks(3 of 8 shown)
Open theme screener
MDTMedtronic plc
$96.59+3.83%
0.1% Above PivotData as of Oct 22, 2026
MRKMerck & Co., Inc.
$147.25-1.75%
4.1% To PivotData as of Oct 22, 2026
Unlock all 8 setups in GLP-1 Stocks
See every active, near-pivot, and forming setup with full charts, advanced filtering, historical performance, alerts, and much more.
All setups and full details Advanced filters & sorting Real-time alerts & notifications
After your 7-day trial: $10/month billed annually ($120/year), or $15/month. No credit card required. No charge unless you upgrade.
Today in GLP-1 Stocks
Data as of Oct 23, 2026Theme Performance
| Today (1D) | +0.18% |
| 5D | +2.14% |
| 1M | -5.44% |
| 3M | +5.26% |
| YTD | -0.64% |
| 1Y | +35.71% |
| vs SPY Benchmark | |
| Today (1D) | +1.36% |
| 1M | -4.94% |
| YTD | -12.67% |
Top Movers
Theme News
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?
zacks.com · 6d ago$DHR
Seeking Clues to Danaher (DHR) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
zacks.com · 6d ago$DHR
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
zacks.com · Oct 15$DHR
Setup coverage is limited to 3 free previews. Rows marked Pro are outside this preview. Unlock Pro to see setup coverage across all 22 stocks.
| # | Ticker | Company | Price | % Change | RS Rating | Market Cap | Setups | Status | Watch |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Merck & Co., Inc. | $147.24 | -1.76% | 84 | $363.66B | (1) | Forming | ||
| 2 | Amgen Inc. | $447.28 | +2.04% | 83 | $241.4B | (1) | Breaking Out | ||
| 3 | Medtronic plc | $96.59 | +3.83% | 74 | $124.01B | (1) | Breaking Out | ||
| 4 | Eli Lilly and Company | $1,306.69 | +2.83% | 84 | $1.23T | Pro | Pro | ||
| 5 | Thermo Fisher Scientific Inc. | $676.54 | -2.52% | 91 | $251.42B | Pro | Pro | ||
| 6 | Abbott Laboratories | $102.51 | +1.99% | 67 | $178.55B | Pro | Pro | ||
| 7 | Pfizer Inc. | $30.42 | +1.91% | 80 | $173.38B | Pro | Pro | ||
| 8 | Danaher Corporation | $229.72 | -1.77% | 85 | $161.49B | Pro | Pro |
About GLP-1 Stocks
Research obesity, GLP-1, metabolic health, diabetes device, medtech, and healthcare platform stocks tied to weight-loss treatment demand.
22 StocksIn this theme
8 SetupsAcross 3 states
Updated DailyAfter market close (~8PM ET)
Popular Segments in this theme
Financial Data & Software Notice: VCP Scanner is an educational financial research database and stock screening software platform. VCP Scanner does not generate, recommend, or package trade decisions, buy/sell signals, or personalized investment advice. Theme baskets are quantitative metric rules, not managed funds or portfolio recommendations. See our Terms of Service and Privacy Policy.